Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PARG | Q86W56 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15911757 | 0.88 | LMNA (0.56) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL15847272 | 0.88 | LMNA (0.56) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL24147138 | 0.85 | TDP1 (0.42) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL25866459 | 0.83 | TDP1 (0.36) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL30450234 | 0.82 | NOS3 (0.43) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL20595229 | 0.82 | NOS3 (0.43) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL15893211 | 0.81 | LMNA (0.56) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL19256875 | 0.81 | TDP1 (0.34) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL803133 | 0.80 | CYP2A6 (0.50) | LMNANR1I2KIF11ALDH1A1HPGD | |
| SCHEMBL4548612 | 0.80 | GRM4 (0.44) | LMNACYP3A4NR1I2GRM4KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227485-A1 | METAL IRIDIUM COMPLEX AND USE THEREOF | GUANGDONG AGLAIA OPTOELECTRONIC MATERIALS CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| WO-2021258875-A1 | METAL IRIDIUM COMPLEX AND USE THEREOF | 广东阿格蕾雅光电材料有限公司 | 2021-12-30 | — | — | WO | disclosed |
| US-20210363141-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2021-11-25 | — | — | US | disclosed |
| US-11028081-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-10654844-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-20200131171-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2020-04-30 | — | — | US | disclosed |
| US-10316029-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| EP-2872590-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2018-11-14 | — | — | EP | disclosed |
| US-20180215749-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2018-08-02 | — | — | US | disclosed |
| US-9951059-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20150263297-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| US-20150263297-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| US-20150175549-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | AERIE PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20140187617-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | AERIE PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-8716310-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| WO-2014008982-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2014-01-16 | — | — | WO | disclosed |
| US-20130158015-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | AERIE PHARMACEUTICALS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8394826-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | AERIE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
| US-20100280011-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187617-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | LMNA 3199/4885CYP3A4 3340/4885MAPT 66/4885 |
| US-10654844-B2 | Dual mechanism inhibitors for the treatment of disease | RHOA, SLC6A2, ROCK2 | LMNA 3199/4885CYP3A4 3340/4885MAPT 66/4885 |
| US-20130158015-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | LMNA 3199/4885CYP3A4 3340/4885MAPT 66/4885 |
| US-20200131171-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | LMNA 3199/4885CYP3A4 3340/4885MAPT 66/4885 |
| US-20150175549-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | LMNA 3199/4885CYP3A4 3340/4885MAPT 66/4885 |
| US-20180215749-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | LMNA 3199/4885CYP3A4 3340/4885MAPT 66/4885 |
| US-20150263297-A1 | Metal Complexes | SOD1, AP1M1, AP3M1 | LMNA 4436/4885CYP3A4 2252/4885MAPT 1084/4885 |
| US-10316029-B2 | Dual mechanism inhibitors for the treatment of disease | RHOA, SLC6A2, ROCK2 | LMNA 3199/4885CYP3A4 3340/4885MAPT 66/4885 |
| US-11028081-B2 | Dual mechanism inhibitors for the treatment of disease | RHOA, SLC6A2, ROCK2 | LMNA 3199/4885CYP3A4 3340/4885MAPT 66/4885 |
| US-20210363141-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | LMNA 3199/4885CYP3A4 3340/4885MAPT 66/4885 |
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | SLC6A2, ROCK2, SLC6A4 | LMNA 1765/4885CYP3A4 1719/4885MAPT 412/4885 |
| US-20100280011-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | LMNA 3199/4885CYP3A4 3340/4885MAPT 66/4885 |
| US-20230227485-A1 | METAL IRIDIUM COMPLEX AND USE THEREOF | IK, INTS9, CYBA | LMNA 3025/4885CYP3A4 1506/4885MAPT 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.